Oxaprozin: a once-daily treatment regimen in rheumatoid arthritis.
The development of oxaprozin provided an opportunity to evaluate the control of inflammation in rheumatoid arthritis by a drug that can be administered once daily. A double-blind 12-week evaluation suggested comparable efficacy between 1,200 mg oxaprozin given as a single daily dose and 3,900 mg ASA given in 4 equally divided doses. A lower incidence of side effects was noted in the oxaprozin group. An open 6-month study substantiated the efficacy and safety of oxaprozin.
D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D006801:Humans; D010080:Oxazoles / Q000008:administration & dosage* / Q000627:therapeutic use; D011422:Propionates / Q000008:administration & dosage / Q000627:therapeutic use
D010080:Oxazoles; D011422:Propionates; D001241:Aspirin